1
TITLE: Pembrolizumab (pembro) for recurrent head and neck squamous cell carcinoma (HNSCC): Post hoc analyses of phase 3 KEYNOTE-040 prior radiation treatment (RT) and disease state.
AUTHORS: Kevin J Harrington; Ezra E W Cohen; Denis Soulieres; Jose Dinis; Lisa F Licitra; Myung Ju Ahn; Ainara Soria; Jean Pascal H Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Jianxin X Lin; Jonathan D Cheng; Ramona F Swaby; Christophe Le Tourneau;
PUBLISHED: 2019, SOURCE: Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) in JOURNAL OF CLINICAL ONCOLOGY, VOLUME: 37, ISSUE: 15
INDEXED IN: WOS
2
TITLE: Updated survival results of the KEYNOTE-040 study of pembrolizumab vs standard-of-care chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma
AUTHORS: Denis Soulieres; Ezra Cohen; Christophe Le Tourneau; Jose Dinis; Lisa Licitra; Myung Ju Ahn; Ainara Soria; Jean Pascal Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Pingye Y Zhang; Jonathan Cheng; Ramona Swaby; Kevin J Harrington;
PUBLISHED: 2018, SOURCE: Annual Meeting of the American-Association-for-Cancer-Research (AACR) in CANCER RESEARCH, VOLUME: 78, ISSUE: 13
INDEXED IN: WOS